01 April 2004
Pharmacokinetics of erythrocyte-bound daunorubicin in patients with acute leukemia
Oleksii A. Skorokhod, Tat’yana Ts. Garmaeva, Victor M. Vitvitsky, Valentin G. Isaev, Elena N. Parovichnikova, Valerii G. Savchenko, Fazoil I. AtaullakhanovMed Sci Monit 2004; 10(4): PI55-64 :: ID: 11632
Abstract
Background:The objective of the present study was in vitro and in vivo investigation of erythrocytes as vehicles for anthracycline antibiotics.Material/Methods: The kinetics of daunorubicin binding with erythrocytes was studied in blood and in washed erythrocyte suspensions from healthy donors and patients with acute leukemia. The effect of daunorubicin on erythrocyte deformability was studied using cell filtration through membranes with 3 Km-diameter cylindrical pores. Erythrocyte-bound daunorubicin (EBD), prepared by equilibrating anticoagulated autologous blood with the antibiotic, was administered (45 or 60 mg/m2 body surface) to 14 leukemic patients as part of the 7+3 or RACOP courses. The pharmacokinetics of daunorubicin and its tolerability were studied.Results: Human erythrocytes bound daunorubicin (rubomycin) in citrated whole blood or in washed saline suspension. The equilibrium erythrocyte/medium daunorubicin concentration ratios (attained in 30–60 min at 37°C) averaged 2.9I0.5 (n=13) in blood and 5.7I0.6 (n=8) in suspension (p<0.001), without any significant difference between the erythrocytes of donors and patients with acute drug-resistant leukemia or leukemic relapses. Incubation of patient blood with daunorubicin (0.5 mg/ml cells) did not affect erythrocyte deformability (filterability). After intravenous administration, the peak drug concentration and its elimination rate were lower for EBD than for free daunorubicin. The patients tolerated EBD better than its standard free form. In nine patients who received three EBD infusions, side effects were less frequent than in those treated with free daunorubicin.
Conclusions: Our results indicate that daunorubicin-loaded erythrocytes are promising for clinical application and deserve further clinical study.
Keywords: Adolescent, Antibiotics, Antineoplastic - administration & dosage, Antibiotics, Antineoplastic - pharmacokinetics, Daunorubicin - administration & dosage, Daunorubicin - pharmacokinetics, Erythrocyte Deformability - drug effects, Erythrocytes - metabolism, Leukemia - blood, Leukemia - drug therapy, Adolescent, Antibiotics, Antineoplastic - pharmacokinetics, Daunorubicin - pharmacokinetics, Erythrocyte Deformability - drug effects, Erythrocytes - metabolism, Leukemia - drug therapy
Editorial
01 April 2025 : Editorial
Editorial: Rapid Testing for the Avian Influenza A(H5N1) Virus is Urgently Required as Infections in Poultry and Dairy Cows are on the Rise, and so is Transmission to HumansDOI: 10.12659/MSM.949109
Med Sci Monit 2025; 31:e949109
In Press
Clinical Research
Dental Students’ Opinions on Use of Artificial Intelligence: A Survey StudyMed Sci Monit In Press; DOI: 10.12659/MSM.947658
Database Analysis
Defining Effect Size Standards in Temporomandibular Joint and Masticatory Muscle ResearchMed Sci Monit In Press; DOI: 10.12659/MSM.948365
Clinical Research
Evaluating Factors Influencing Periodontal Bone Loss Using Cone Beam Computed Tomography: A Retrospective S...Med Sci Monit In Press; DOI: 10.12659/MSM.947759
Database Analysis
Prognostic Significance and Immune Environment Analysis Using PANoptosis Molecular Clustering in Gastric Ca...Med Sci Monit In Press; DOI: 10.12659/MSM.947710
Most Viewed Current Articles
17 Jan 2024 : Review article 8,225,070
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research 703,027
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Mar 2024 : Editorial 30,424
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...DOI :10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
28 Jan 2024 : Review article 24,191
A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and FutureDOI :10.12659/MSM.943912
Med Sci Monit 2024; 30:e943912